Premium
Evaluation of rhBMP‐2 and Natural Latex as Potential Osteogenic Proteins in Critical Size Defects by Histomorphometric Methods
Author(s) -
Issa João Paulo Mardegan,
Defino Helton Luiz Aparecido,
Netto Joaquim Coutinho,
Volpon José Batista,
Regalo Simone Cecílio Hallak,
Iyomasa Mamie Mizusaki,
Siéssere Selma,
Tiossi Rodrigo
Publication year - 2010
Publication title -
the anatomical record: advances in integrative anatomy and evolutionary biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.678
H-Index - 62
eISSN - 1932-8494
pISSN - 1932-8486
DOI - 10.1002/ar.21097
Subject(s) - calvaria , gelatin , parietal bone , bone morphogenetic protein 2 , chemistry , human bone , bone morphogenetic protein , bone formation , in vivo , anatomy , medicine , skull , biology , biochemistry , in vitro , microbiology and biotechnology , gene
This in vivo study evaluated the osteogenic potential of two proteins, recombinant human bone morphogenetic protein‐2 (rhBMP‐2) and a protein extracted from natural latex ( Hevea brasiliensis , P‐1), and compared their effects on bone defects when combined with a carrier or a collagen gelatin. Eighty‐four (84) Wistar rats were divided into two groups, with and without the use of collagen gelatin, and each of these were divided into six treatment groups of seven animals each. The treatment groups were: (1) 5 μg of pure rhBMP‐2; (2) 5 μg of rhBMP‐2/monoolein gel; (3) pure monoolein gel; (4) 5 μg of pure P‐1; (5) 5 μg of P‐1/monoolein gel; (6) critical bone defect control. The animals were anesthetized and a 6 mm diameter critical bone defect was made in the left posterior region of the parietal bone. Animals were submitted to intracardiac perfusion after 4 weeks and the calvaria tissue was removed for histomorphometric analysis. In this experimental study, it was concluded that rhBMP‐2 allowed greater new bone formation than P‐1 protein and this process was more effective when the bone defect was covered with collagen gelatin ( P < 0.05). Anat Rec, 2010. © 2010 Wiley‐Liss, Inc.